TEK2day FINANCE Open Terminal →

Champions Oncology, Inc. (CSBR)

NCM · Healthcare · Biotechnology

$6.50 +1.25%

Closing price as of 2026-06-12 · Source: TEK2day Finance

1-Year Price History +8.2% over period
$7$6$6$6$6 2026-052026-052026-052026-062026-06

Key Metrics

Market Cap
$90.3M
Shares Outstanding
13.9M
P/S (TTM)
1.6x
Exchange
NCM
Currency
USD

About Champions Oncology, Inc.

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Quarterly Financials

Metric2025-04-302025-07-312025-10-312026-01-31
Revenue12.4M14.0M15.0M16.6M
Gross Profit5.1M6.0M7.8M7.7M
Operating Income-1.7M-507K185K-187K
Net Income-1.8M-466K299K-279K
Diluted EPS$-0.13$-0.03$0.02$-0.02

Annual Financials

Metric2022-04-302023-04-302024-04-302025-04-30
Revenue49.1M53.9M50.2M56.9M
Gross Profit25.5M24.3M20.8M28.6M
Operating Income607K-4.4M-6.9M4.8M
Net Income548K-5.3M-7.3M4.7M
Diluted EPS$0.04$-0.39$-0.54$0.33
Want live quotes, estimates, SEC filings, and CEO analytics for CSBR?
The free TEK2day terminal runs in your browser — type /CSBR to get started.
Open CSBR in the Terminal →